Publicly traded Axovant Sciences (NASDAQ:AXON) a clinical-stage gene therapy venture, reported topline results of the 34-patient exploratory phase 2 clinical trial of nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy Body Dementia (LBD). The primary efficacy endpoint of reduction in frequency of RBD events as measured by sleep laboratory video assessment was not met. Follow the link for the remainder of the press release. Who is Axovant? A clinical-stage company that develops small molecule drugs to treat neurological disorders. The venture was founded by former hedge fund analyst Vivek Ramaswamy in 2014 as a whole owned subsidiary of Roivant Sciences. Lewy Body Dementia impacts about one million people in the United States. Axovant floated an IPO in 2014 and raised $315 million. It has received critiques from notable stock analysts.